dc.contributor.author | Padron-Barthe, Laura | |
dc.contributor.author | Villalba-Orero, Maria | |
dc.contributor.author | Gomez-Salinero, Jesus M. | |
dc.contributor.author | Acin-Perez, Rebeca | |
dc.contributor.author | Cogliati, Sara | |
dc.contributor.author | Lopez-Olaneta, Marina | |
dc.contributor.author | Ortiz-Sanchez, Paula | |
dc.contributor.author | Bonzon-Kulichenko, Elena | |
dc.contributor.author | Vazquez, Jesus | |
dc.contributor.author | Garcia-Pavia, Pablo | |
dc.contributor.author | Rosenthal, Nadia | |
dc.contributor.author | Enriquez, Jose Antonio | |
dc.contributor.author | Lara-Pezzi, Enrique | |
dc.date.accessioned | 2018-11-22T08:10:53Z | |
dc.date.available | 2018-11-22T08:10:53Z | |
dc.date.issued | 2018 | |
dc.identifier | ISI:000424512200009 | |
dc.identifier.citation | J Am Coll Cardiol. 2018; 71(6):654-667 | |
dc.identifier.issn | 0735-1097 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/6687 | |
dc.description.abstract | BACKGROUND In response to pressure overload, the heart develops ventricular hypertrophy that progressively decompensates and leads to heart failure. This pathological hypertrophy is mediated, among others, by the phosphatase calcineurin and is characterized by metabolic changes that impair energy production by mitochondria. OBJECTIVES The authors aimed to determine the role of the calcineurin splicing variant CnA beta 1 in the context of cardiac hypertrophy and its mechanism of action. METHODS Transgenic mice overexpressing CnAb1 specifically in cardiomyocytes and mice lacking the unique C-terminal domain in CnA beta 1 (CnA beta 1(Delta i12) mice) were used. Pressure overload hypertrophy was induced by transaortic constriction. Cardiac function was measured by echocardiography. Mice were characterized using various molecular analyses. RESULTS In contrast to other calcineurin isoforms, the authors show here that cardiac-specific overexpression of CnA beta 1 in transgenic mice reduces cardiac hypertrophy and improves cardiac function. This effect is mediated by activation of serine and one-carbon metabolism, and the production of antioxidant mediators that prevent mitochondrial protein oxidation and preserve ATP production. The induction of enzymes involved in this metabolic pathway by CnAb1 is dependent on mTOR activity. Inhibition of serine and one-carbon metabolism blocks the beneficial effects of CnA beta 1. CnA beta 1(Delta i12) mice show increased cardiac hypertrophy and declined contractility. CONCLUSIONS The metabolic reprogramming induced by CnAb1 redefines the role of calcineurin in the heart and shows for the first time that activation of the serine and one-carbon pathway has beneficial effects on cardiac hypertrophy and function, paving the way for new therapeutic approaches. (J Am Coll Cardiol 2018; 71: 654-67) (C) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/). | |
dc.description.sponsorship | This work was supported by grants from the European Union (CardioNeT-ITN-289600 and CardioNext-608027 to Dr. Lara-Pezzi; Meet-ITN-317433 to Dr. Enriquez; UE0/MCA1108 to Dr. Acin-Perez), from the Spanish Ministry of Economy and Competitiveness (SAF2015-65722-R and SAF2012-31451 to Dr. Lara-Pezzi; SAF2015-71521-REDC, BFU2013-50448, and SAF2012-32776 to Dr. Enriquez; RyC-2011-07826 to Dr. Acin-Perez; BIO2012-37926 and BIO2015-67580-P to Dr. Vazquez), from the Spanish Carlos III Institute of Health (CPII14/00027 to Dr. Lara-Pezzi; RD12/0042/066 to Drs. Garcia-Pavia and Lara-Pezzi), from the Regional Government of Madrid (2010-BMD-2321 ``Fibroteam´´ to Dr. Lara-Pezzi; 2011-BMD-2402 ``Mitolab´´ to Dr. Enriquez) and the FIS-ISCIII (PRB2-IPT13/0001 and RD12/0042/0056-RIC-RETICS to Dr. Vazquez). This work was also supported by the Plan Estatal de IthornDthornI 2013-2016-European Regional Development Fund (FEDER) ``A way of making Europe,´´ Spain. The CNIC is supported by the Spanish Ministry of Economy and Competitiveness and by the Pro-CNIC Foundation and is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0505). Drs. Vazquez and Garcia-Pavia have served as consultants for VL39. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Padron-Barthe, Villalba-Orero, and Gomez-Salinero contributed equally to this work and are joint first authors. Robyn Shaw, MD, PhD, served as Guest Editor for this paper. | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.type.hasVersion | VoR | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Cardiac function | |
dc.subject | Cell signaling | |
dc.subject | Hypertrophy | |
dc.subject | Metabolism | |
dc.title | Activation of Serine One-Carbon Metabolism by Calcineurin A beta 1 Reduces Myocardial Hypertrophy and Improves Ventricular Function | |
dc.type | journal article | |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 29420962 | |
dc.format.volume | 71 | |
dc.format.page | 654-667 | |
dc.identifier.doi | 10.1016/j.jacc.2017.11.067 | |
dc.contributor.funder | Unión Europea. Comisión Europea | |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Fundación ProCNIC | |
dc.description.peerreviewed | Sí | |
dc.identifier.e-issn | 1558-3597 | |
dc.relation.publisherversion | https://doi.org/10.1016/j.jacc.2017.11.067 | |
dc.identifier.journal | Journal of the American College of Cardiology | |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Regulación Molecular de la Insuficiencia Cardiaca | |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Genética Funcional del Sistema de Fosforilación Oxidativa | |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Proteómica cardiovascular | |
dc.repisalud.institucion | CNIC | |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2015-65722-R | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2012-31451 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2015-71521-REDC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/BFU2013-50448 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2012-32776 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RyC-2011-07826 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/BIO2012-37926 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/BIO2015-67580-P | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CPII14/00027 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD12/0042/066 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PRB2-IPT13/0001 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD12/0042/0056 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/289600/EU | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/317433/EU | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/608027/EU | es_ES |
dc.rights.accessRights | open access | es_ES |